Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:06:44 01/06/2024 am IST			5-day change	1st Jan Change
3.2 ^USD	-0.62%		-.--%	+267.82%

29/05	Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial	CI
10/05	Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

April 18, 2023 at 02:35 am IST

Kiromic BioPharma, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 34.73 million compared to USD 25.59 million a year ago. Basic loss per share from continuing operations was USD 64.42 compared to USD 67.82 a year ago.

Diluted loss per share from continuing operations was USD 64.42 compared to USD 67.82 a year ago.

Latest news about Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial	29/05	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	01/05	CI
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	24/04	CI
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	02/04	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	02/04	CI
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial	19/03	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	14/02	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	12/02	CI
Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer	29/01	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	08/01	CI
Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial	05/01	CI
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel? for the Treatment of Non-Small Cell Lung Cancer	14/12	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	12/12	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Kiromic Biopharma, Inc. Announces Deltacel?? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center	09/11	CI
Kiromic BioPharma, Inc. and Beverly Hills Cancer Center Enter Clinical Trial Agreement	23/23/23	CI
Kiromic Biopharma, Inc. Appoints Brian Hungerford as Chief Financial Officer	04/23/04	CI
Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding	27/23/27	CI
Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from S&P TMI Index	18/23/18	CI
Kiromic Biopharma Shares Suspended From Trading on Nasdaq	14/23/14	MT
Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index	13/23/13	CI
Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding	25/23/25	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI

Chart Kiromic BioPharma, Inc.

Duration

Period

More charts

Company Profile

Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KIROMIC BIOPHARMA, INC.	+267.82%	4.97M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B

Bio Therapeutic Drugs